Medicare Coverage Advisers Split On Renal Artery Stenting
This article was originally published in The Gray Sheet
Executive Summary
CMS' Medicare Evidence Development Coverage Advisory Committee (MedCAC) could not reach consensus on whether Medicare coverage of angioplasty and stenting to treat renal artery disease should be limited to patients in clinical trials